Fractional Concentration of Exhaled NO(FENO) to Direct Montelukast Treatment of Sub-acute Cough
Status:
Unknown status
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology
and wide-ranging. Cough is usually divided into three categories by time: acute cough,
subacute cough and chronic cough. Subacute has a 3~8 weeks course of disease. Its main
etiology is postinfectious cough, which is mostly secondary to viral infection.Considering
its overexpression in postinfectious patient, Cysteinyl leukotriene (CysLTs) plays a role in
gathering eosinophils to respiratory. The level of FENO has a significant correlation with
inflammatory airway eosinophils. While CysLTs overexpressed in vivo, the level of FENO may
increase. Montelukast, as CysLTs-receptor-1 antagonists， plays a role of controlling airway
inflammation and decrease airway high activity by suppressing the biological activity of
CysLTs. It is effective in theory to therapy sub-acute cough by Montelukast, to short the
course and to relieve cough symptoms as soon as possible. The aim is to research whether FENO
can be used as a biomarker to optimized treatment regimen of sub-acute cough.